Key result
The baseline risk of VTE within 4 weeks of urological cancer surgery varied widely by procedure, from 0.2-0.9% in robotic prostatectomy without PLND to 2.6-11.6% in cystectomies.
Why the study?
What are the baseline risks of symptomatic VTE and bleeding requiring reoperation in patients undergoing urological cancer surgery to guide thromboprophylaxis?
Population
Patients undergoing urological cancer surgery (71 studies reporting on 14 urological cancer procedures)
Comparison
Pharmacological thromboprophylaxis vs No prophylaxis (baseline risk)
Design
Meta-analysis
Follow-up
within 4 weeks of surgery
Authors
Loading...
Contemporary baseline VTE and bleeding risks inform thromboprophylaxis decisions in urological cancer surgery; leaves open randomized confirmation of net benefit.
Meta-Analysis
Yes
What are the baseline risks of symptomatic VTE and bleeding requiring reoperation in patients undergoing urological cancer surgery to guide thromboprophylaxis?
Extended thromboprophylaxis is warranted in high-risk urological cancer procedures like cystectomy, but not in low-risk procedures like robotic prostatectomy without PLND.
Tikkinen et al. (2017) conducted a meta-analysis in Urological cancer. Urological cancer surgery was evaluated on Symptomatic VTE and bleeding requiring reoperation. The baseline risk of VTE within 4 weeks of urological cancer surgery varied widely by procedure, from 0.2-0.9% in robotic prostatectomy without PLND to 2.6-11.6% in cystectomies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: